Bolt Biotherapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Bolt Biotherapeutics, Inc. (BOLT) had Operating Lease, Weighted Average Discount Rate, Percent of 11.90% as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 11.90%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 11.90%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 11.90%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 11.90%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 11.90% 10-Q · filed 2026-08-11 |
| 2026-03-31 | 11.90% 10-Q · filed 2026-05-12 |
| 2025-12-31 | 11.90% 10-Q · filed 2026-08-11 |
| 2025-09-30 | 11.90% 10-Q · filed 2025-11-12 |
| 2025-06-30 | 11.90% 10-Q · filed 2025-08-14 |
| 2025-03-31 | 11.90% 10-Q · filed 2025-05-12 |
| 2024-12-31 | 11.90% 10-K · filed 2026-03-12 |
| 2024-09-30 | 11.30% 10-Q · filed 2024-11-12 |
| 2024-06-30 | 11.20% 10-Q · filed 2024-08-13 |
| 2024-03-31 | 11.10% 10-Q · filed 2024-05-14 |
| 2023-12-31 | 11.10% 10-K · filed 2025-03-24 |
| 2023-09-30 | 11.10% 10-Q · filed 2023-11-09 |
| 2023-06-30 | 11.00% 10-Q · filed 2023-08-07 |
| 2023-03-31 | 11.00% 10-Q · filed 2023-05-11 |
| 2022-12-31 | 11.00% 10-K · filed 2024-03-21 |
| 2022-09-30 | 10.90% 10-Q · filed 2022-11-10 |
| 2022-06-30 | 11.10% 10-Q · filed 2022-08-10 |
| 2022-03-31 | 11.00% 10-Q · filed 2022-05-12 |
| 2021-12-31 | 10.70% 10-K · filed 2023-03-29 |
| 2021-09-30 | 10.90% 10-Q · filed 2021-11-09 |
| 2021-06-30 | 10.80% 10-Q · filed 2021-08-12 |
| 2021-03-31 | 9.60% 10-Q · filed 2021-05-13 |
| 2020-12-31 | 9.50% 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |